pcDNA3.1-MS2-Tet1-CD Citations (4)
Originally described in: A CRISPR-based approach for targeted DNA demethylation.Xu X, Tao Y, Gao X, Zhang L, Li X, Zou W, Ruan K, Wang F, Xu GL, Hu R Cell Discov. 2016 May 3;2:16009. doi: 10.1038/celldisc.2016.9. eCollection 2016. PubMed Journal
Articles Citing pcDNA3.1-MS2-Tet1-CD
| Articles |
|---|
Enhanced CRISPR-based DNA demethylation by Casilio-ME-mediated RNA-guided coupling of methylcytosine oxidation and DNA repair pathways.
Taghbalout A, Du M, Jillette N, Rosikiewicz W, Rath A, Heinen CD, Li S, Cheng AW.
Nat Commun. 2019 Sep 20;10(1):4296. doi: 10.1038/s41467-019-12339-7.
PubMed
Associated Plasmids |
| Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. Deutschmeyer V, Breuer J, Walesch SK, Sokol AM, Graumann J, Bartkuhn M, Boettger T, Rossbach O, Richter AM. Clin Epigenetics. 2019 Dec 4;11(1):182. doi: 10.1186/s13148-019-0774-2. PubMed |
| A methylation functional detection hepatic cell system validates correlation between DNA methylation and drug-induced liver injury. Wei Y, Huai C, Zhou C, Gao Y, Chen L, Zhou W, Wei M, Qin S. Pharmacogenomics J. 2020 Feb 7. pii: 10.1038/s41397-020-0160-7. doi: 10.1038/s41397-020-0160-7. PubMed |
| Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma. Sgro A, Cursons J, Waryah C, Woodward EA, Foroutan M, Lyu R, Yeoh GCT, Leedman PJ, Blancafort P. Clin Epigenetics. 2023 Apr 29;15(1):73. doi: 10.1186/s13148-023-01482-0. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.